Mutations in specific genes (FLT3 ITD, NPM1, TP53, ASXL1) have been reported to stratify CN-AML into prognostic subgroups [70]; however, ~24% of CN-AML cases lack detectable mutations in these genes [71]. The gene discussed is FLT3; the disease is acute myeloid leukemia.